CastleVax is at the forefront of developing a pioneering mucosal vaccine platform that utilizes Newcastle Disease Virus (NDV) as a viral vector. This innovative approach allows for the rapid creation of safe and highly immunogenic vaccines that can be easily administered. The platform has been tested in the context of the COVID-19 pandemic, demonstrating its potential to produce effective vaccines that induce mucosal immunity, a critical aspect often overlooked in traditional systemic vaccine delivery methods. By focusing on mucosal responses, CastleVax aims to enhance the efficacy of vaccines against respiratory diseases, ultimately preparing the world for future pandemics.

The company's lead product candidate, the NDV-HXP-S vaccine, showcases significant advancements over existing COVID-19 vaccines. In clinical studies, it has shown comparable performance to leading vaccines while offering unique advantages, such as a robust mucosal immune response and superior antigen design. CastleVax is also expanding its pipeline to include vaccines for other viruses, including Respiratory Syncytial Virus (RSV) and Norovirus, indicating a commitment to addressing a wide range of infectious diseases. Through its innovative technology, CastleVax aims to revolutionize vaccine development and improve global health preparedness.

United States

CastleVax uses Newcastle Disease Virus (NDV) as a platform for rapidly developing safe and highly immunogenic viral vectors for use as vaccines, that are easy to deliver and store, and can be administered via injection or intranasally.

CastleVax

Company Details